Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, PMID: 28249141
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults, PMID: 33085860
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia, PMID: 29358182
A review of blinatumomab, a novel immunotherapy, PMID: 26607163
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy, PMID: 27050240
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy, PMID: 33173373
Recent advances on blinatumomab for acute lymphoblastic leukemia, PMID: 31709129
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia, PMID: 27998223
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL, PMID: 30796026
Blinatumomab for infant acute lymphoblastic leukemia, PMID: 32043146
Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, PMID: 30565020
Blinatumomab-Associated Neurological Adverse Events, PMID: 32902938
Blinatumomab, PMID: 31643524
Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults, PMID: 33153370
Blinatumomab: a historical perspective, PMID: 22940266
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study, PMID: 25524800
Blinatumomab, PMID: 29999804
How we infuse blinatumomab, PMID: 32573958
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia, PMID: 31626339
Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease, PMID: 33256906
Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia, PMID: 30947585
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL, PMID: 32881995
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, PMID: 31002989
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study, PMID: 31433496
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia, PMID: 32094465
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia, PMID: 33098744
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab, PMID: 33141929
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma, PMID: 26755709
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage, PMID: 30307611
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia, PMID: 32619115
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy, PMID: 31738832
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia, PMID: 30831480
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy, PMID: 32103893
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy, PMID: 23678006
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study, PMID: 26884582
Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications, PMID: 27209293
Blinatumomab for the treatment of B-cell lymphoma, PMID: 25739952
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis, PMID: 30985931
Blinatumomab for lymphoblastic leukaemia, PMID: 27990053
Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia, PMID: 28494518
Blinatumomab: first global approval, PMID: 25637301
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies, PMID: 30380973
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia, PMID: 28927784
Blinatumomab: A novel, bispecific, T-cell engaging antibody, PMID: 26683683
Targeting non-Hodgkin lymphoma with blinatumomab, PMID: 28532177
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study, PMID: 28355115
Pediatric blinatumomab preparation: Risk assessment on SmPC for software compliance, PMID: 33106105
Blinatumomab for the treatment of acute lymphoblastic leukemia, PMID: 26383529
Blinatumomab provoked fatal heart failure, PMID: 27816725
Blinatumomab-associated vasculitis, PMID: 28879223
Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents., PMID:40527981
Successful treatment with decompressive laparotomy for abdominal compartment syndrome induced by asparaginase-associated pancreatitis in a pediatric patient with acute lymphoblastic leukemia: a case report., PMID:40519724
Pooled biomarker analysis of the association of baseline T regulatory cells with response and T-cell recovery profiles with blinatumomab treatment., PMID:40515477
From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies., PMID:40508128
Blinatumomab and better BCR::ABL1 inhibition begets better bone marrow transplant outcomes., PMID:40501389
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center., PMID:40500615
Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia. Reply., PMID:40499182
Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia., PMID:40499181
Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia., PMID:40494331
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission., PMID:40492422
Blinatumomab Use in Pediatric B-ALL: Where are we now?, PMID:40489801
Acute Lymphoid Leukemia: Is Transplant Indicated for Philadelphia Chromosome Positive ALL?, PMID:40488828
High sensitivity charge heterogeneity characterization of blinatumomab product by imaged capillary isoelectric focusing with native UV fluorescence detection., PMID:40483960
Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243
Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease., PMID:40445300
Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation., PMID:40437770
Blinatumomab Versus Chemotherapy for Post-Induction Consolidation in First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials., PMID:40436683
Navigating B-ALL in the Era of Blinatumomab., PMID:40435433
Efficacy and safety of blinatumomab in Chinese patients with relapsed/refractory B-cell acute lymphoblastic leukemia: a single-center retrospective study., PMID:40421088
Acute Pancreatitis Associated With Blinatumomab Treatment in a Patient With Acute Lymphoblastic Leukemia., PMID:40406756
Blitzing ALL with blinatumomab., PMID:40402527
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring., PMID:40377367
Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e13a3 fusion transcripts in a patient with pre-existing essential thrombocythemia: a case report and literature review., PMID:40376591
Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20., PMID:40374821
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab., PMID:40369607
The role of blinatumomab in adult acute B lymphoblastic leukaemia., PMID:40368871
[Clinical analysis of 16 cases of adult acute B-lymphoblastic leukemia treated with blinatumomab]., PMID:40355357
Treatment of Older Patients With ALL., PMID:40354595
Overcoming Chemotherapy Resistance in EBF1-PDGFRB-Positive B-ALL: A Novel Therapeutic Approach Using Dasatinib and Blinatumomab., PMID:40350550
The Role of Transplant for Philadelphia-positive B-cell Acute Lymphoblastic Leukemia in 2025., PMID:40343686
Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia., PMID:40324358
The evolving therapeutic revolution in adult acute lymphoblastic leukemia., PMID:40323723
Recent development in bispecific antibody immunotherapy for hematological malignancies., PMID:40320222
Feedback-responsive cell factories for dynamic modulation of the unfolded protein response., PMID:40316547
Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy., PMID:40316226
Management of Adult Acute Lymphoblastic Leukemia: A Review., PMID:40310617
Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adults., PMID:40306011
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19., PMID:40304059
Tyrosine kinase inhibitors with blinatumomab versus chemotherapy in Philadelphia-positive acute B-lymphoblastic leukemia., PMID:40304038
Bispecific antibodies in immunotherapy for acute leukemia: latest updates from the 66th annual meeting of the American society of hematology, 2024., PMID:40270605
T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia., PMID:40267221
Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients., PMID:40232601
Improved post-transplant outcomes since 2000 for Ph-positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party., PMID:40224161
Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18)., PMID:40222876
KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges., PMID:40207717
Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review., PMID:40202540
Characteristics of second primary malignancies following bispecific antibodies therapy., PMID:40187754
Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia., PMID:40181350
B-cell Acute Lymphoblastic Leukemia Presenting as Acute Liver Injury: A Case Report., PMID:40171360
Integrating Blinatumomab in the Frontline Treatment in B-Cell Acute Lymphoblastic Leukemia: A New Era in Therapeutic Management., PMID:40142863
For research use only. Not for human or drug use.
